JNJ 10397049

Key Product Details

Product Description

JNJ 10397049 is a selective OX₂ receptor antagonist (pIC₅₀ = 7.4 for chimeric OX₂ receptors; pK_B values are 5.9 and 8.5 for OX₁ and OX₂ receptors respectively). Shows no significant activity in a panel of over 50 other neurotransmitters and neuropeptide receptors. Achieves high level of OX₂ receptor occupancy in the rat brain; exhibits sleep-promoting effects in rats.

Product Specifications for JNJ 10397049

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for JNJ 10397049

The following data is based on the product molecular weight 484.18.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.07 mL	10.33 mL	20.65 mL
5 mM	0.41 mL	2.07 mL	4.13 mL
10 mM	0.21 mL	1.03 mL	2.07 mL
50 mM	0.04 mL	0.21 mL	0.41 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 12 publications citing the usage of this product.

• Tran Chimeric, mutant orexin receptors show key interactions between orexin receptors, peptides and antagonists. Eur.J.Pharmacol. 2011 PMID: 21679703
• Gozzi Functional magnetic resonance imaging reveals different neural substrates for the effects of orexin-1 and orexin-2 receptor antagonists. PLoS ONE 2011 PMID: 21307957
• Dugovic Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat. J.Pharmacol.Exp.Ther. 2009 PMID: 19363060

Product Documents for JNJ 10397049